Market Analysis and Price Projections for Erythromycin Ethylsuccinate (NDC: 62559-0440)
Overview of Erythromycin Ethylsuccinate
Erythromycin Ethylsuccinate, with the NDC code 62559-0440, is a prescription drug manufactured and distributed by ANI Pharmaceuticals, Inc. It is an oral granule formulation for suspension, containing 200 mg of erythromycin ethylsuccinate per 5 mL[1].
Current Market Trends
Price Increases in Prescription Drugs
The pharmaceutical market is characterized by periodic price increases, particularly in January and July of each year. According to the ASPE analysis, the largest number of price increases occurs in January, with over 3,000 drugs experiencing price hikes in 2022. July also sees significant price increases, although the number of affected drugs is lower[2].
Specific Price Changes
While the specific price history of Erythromycin Ethylsuccinate (NDC: 62559-0440) is not detailed in the available sources, it is part of a broader trend where many prescription drugs experience price increases. For instance, in January 2022, the average price increase was nearly $150 per drug, representing a 10% increase[2].
Projected Price Inflation
Overall Pharmaceutical Market
For 2025, Vizient projects an overall drug price inflation rate of 3.81%. This projection is influenced by factors such as the expanding indications of previously approved medications and the introduction of high-cost cell and gene therapies[4].
Impact on Generic and Specialty Drugs
Generic drugs like Erythromycin Ethylsuccinate may experience different inflation rates compared to specialty and high-cost therapies. However, the overall trend suggests that even generic drugs can see price increases, albeit typically at a lower rate than their specialty counterparts.
Factors Influencing Price Projections
Expanding Indications and New Therapies
The expansion of indications for existing drugs, such as semaglutide, can significantly impact pharmacy spend and may influence the pricing of other medications. New therapies, especially high-cost cell and gene therapies, are also expected to drive up costs and potentially affect the pricing environment for all drugs[4].
Economic and Inflationary Pressures
General inflation rates, such as the 8.5% increase in the Consumer Price Index (CPI-U) between July 2021 and July 2022, can also influence drug prices. While the average July 2022 price increase was slightly below the inflation rate, many drugs still saw significant price hikes[2].
AI and Data Trends in Pharma
The increasing use of artificial intelligence (AI) and external data in pharmaceutical companies could impact pricing strategies. For instance, AI can help in predicting market trends and optimizing pricing models. However, the direct impact of AI on the pricing of specific drugs like Erythromycin Ethylsuccinate is less clear and would depend on how these technologies are integrated into the pricing decision-making process[3].
Key Takeaways
- Price Increases: Erythromycin Ethylsuccinate, like many other prescription drugs, is likely to experience price increases, particularly in January and July.
- Overall Inflation: The projected 3.81% drug price inflation rate for 2025 suggests that Erythromycin Ethylsuccinate could see a moderate price increase.
- Market Trends: Expanding indications for other drugs and the introduction of high-cost therapies may indirectly influence the pricing of generic drugs.
- AI and Data: The adoption of AI and external data could refine pricing strategies but may not directly impact the price of Erythromycin Ethylsuccinate in the short term.
FAQs
1. What is the current dosage form and strength of Erythromycin Ethylsuccinate (NDC: 62559-0440)?
- Erythromycin Ethylsuccinate is available as an oral granule for suspension, with a strength of 200 mg per 5 mL[1].
2. When are the most significant price increases for prescription drugs typically observed?
- The most significant price increases for prescription drugs typically occur in January and July of each year[2].
3. What is the projected drug price inflation rate for 2025 according to Vizient?
- Vizient projects an overall drug price inflation rate of 3.81% for 2025[4].
4. How might the use of AI and external data impact drug pricing?
- AI and external data can help pharmaceutical companies in predicting market trends and optimizing pricing models, though the direct impact on specific drug prices is less clear[3].
5. What factors are influencing the pricing environment for pharmaceuticals in 2025?
- Factors include expanding indications for existing drugs, the introduction of high-cost cell and gene therapies, and general economic and inflationary pressures[2][4].
Sources
- FDA Report: NDC 62559-630 Oral Granule, For Suspension Erythromycin Ethylsuccinate[1].
- ASPE Brief: Price Increases for Prescription Drugs, 2016-2022[2].
- Intelligencia AI Blog: 2025 Pharma Predictions: AI, Health Tech, and Data Trends to Watch[3].
- Vizient News Release: Vizient projects drug price inflation at 3.81%[4].
